IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
87 hedge funds and large institutions have $514M invested in IGM Biosciences in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 33 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
18% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $1.08M
1.83% more ownership
Funds ownership: 65.94% → 67.77% (+1.8%)
19% less funds holding
Funds holding: 107 → 87 (-20)
53% less capital invested
Capital invested by funds: $1.11B → $514M (-$591M)
61% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 33
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$17.4M |
| 2 |
AG
Artal Group
Luxembourg
|
+$7.45M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.45M |
| 4 |
Millennium Management
New York
|
+$7.37M |
| 5 |
D.E. Shaw & Co
New York
|
+$5.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$8.23M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$7.39M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.88M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$4.53M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.79M |
IGMS Hedge Fund Activity: Q4 2021 in Review
87 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q4 2021, worth a combined $514M — down 53% from $1.11B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of IGMS and 13 opened new positions — a net loss of 20 holders — while 20 trimmed existing stakes and 37 added.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $17.4M. The largest seller was Woodline Partners, cutting an estimated $8.23M.
- 87 institutional investors held IGM Biosciences (IGMS) as of Q4 2021, down from 107 in Q3 2021.
- Funds reported $514M of IGM Biosciences stock for Q4 2021, down 53% quarter-over-quarter.
- 13 funds opened new IGM Biosciences positions in Q4 2021 and 33 closed out, a net change of -20 holders.
- The largest IGM Biosciences buyer in Q4 2021 was Pictet Asset Management (Switzerland), an estimated $17.4M added.
- The largest IGM Biosciences seller in Q4 2021 was Woodline Partners, an estimated $8.23M sold.
Based on aggregated 13F filings for Q4 2021.